

SEQUENCE LISTING

<110> Abbott Laboratories
Henkin, Jack
Haviv, Fortuna
Bradley, Michael F.
Kalvin, Douglas M.
Schneider, Andrew J.

<120> PEPTIDE ANTIANGIOGENIC DRUGS

<130> 6356.US.C1

<140> Not yet assigned
<141> 2004-01-23

<150> US 09/447,226
<151> 1999-11-22

<150> US 09/316,888
<151> 1999-05-21

<150> US 60/126,546
<151> 1999-03-26

<150> US 60/086,536
<151> 1998-05-28

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Antiangiogenetic Peptide

<221> VARIANT
<222> (1)...(1)
<223> Xaa = Ala, Asn, Cit, Gln, Glu, N^ε-Gly, Met,
N-methylalanyl, Pro, pyro-Glu, Sar, Ser, or Thr at
position 1

<221> VARIANT
<222> (2)...(2)
<223> Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,
or Ser at position 2

<221> VARIANT
<222> (3)...(3)
<223> Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,
Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,
or Cys at position 3

<221> VARIANT

```

<222> (4)...(4)
<223> Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at
        position 4

<221> VARIANT
<222> (5)...(5)
<223> Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,
        allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
        Nva, Octylgly, Orn, Phe(4-CH2OH), Pro, Ser, Thr,
        Trp, Tyr, Pen, or Cys at position 5

<221> VARIANT
<222> (6)...(6)
<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
        Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
        Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
        at position 6

<221> VARIANT
<222> (6)...(6)
<223> 6 Cont'd:
        Xaa = Met(O2), Met(O), Met, Nor, Nva, Octylgly,
        Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
        Tyr, Val, Pen, or Cys at position 6

<221> VARIANT
<222> (7)...(7)
<223> Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly,
        Hser, Ile, alloIle, Leu, Lys(Ac), Met, 1-Nal,
        2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,
        Val, Pen, or Cys at position 7

<221> VARIANT
<222> (8)...(8)
<223> Xaa = Aminopyrimidinobutanoyl, Ala(3-guanidino),
        Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],
        Arg, arginyl(NGNG'diethyl), Cit, Cha(4-NIsp),
        Gly[4-pip(N-amido)], at position 8

<221> VARIANT
<222> (8)...(8)
<223> 8 Cont'd:
        Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,
        Orn(Isp), Orn(Nic), Orn(2-imidazo),
        Phe(4-CH2NHIsp), Phe(4-guanidino), or Phe(4-NIsp)
        at position 8

<221> VARIANT
<222> (9)...(9)
<223> Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile,
        Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at
        position 9

<221> VARIANT
<222> (10)...(10)
<223> Xaa = azaglycylamide, glycylamide,
        glycylethylamide, sarcosylamide, serylamide at
        position 10

<400> 1

```

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10

<210> 2
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Antiangiogenetic peptide

<221> VARIANT
 <222> (1)...(1)
 <223> Xaa = sarcosyl at position 1

<221> VARIANT
 <222> (6)...(6)
 <223> Xaa = norvaline at position 6

<400> 2
 Xaa Gly Val Ile Thr Xaa Ile Arg Pro
 1 5

<210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Antiangiogenetic peptide

<221> VARIANT
 <222> (1)...(1)
 <223> Xaa = sarcosyl at position 1

<221> VARIANT
 <222> (6)...(6)
 <223> Xaa = norvaline at position 6

<400> 3
 Xaa Gly Val Gly Thr Xaa Ile Arg Pro
 1 5

<210> 4
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Antiangiogenetic peptide

<221> VARIANT
 <222> (1)...(1)
 <223> Xaa = sarcosyl at position 1

<221> VARIANT
 <222> (4)...(4)

<223> Xaa = allo-isoleucyl at position 4

<221> VARIANT

<222> (6)...(6)

<223> Xaa = norvaline at position 6

<400> 4

Xaa Gly Val Xaa Thr Xaa Ile Arg Pro

1

5

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Antiangiogenetic peptide

<221> VARIANT

<222> (1)...(1)

<223> Xaa = sarcosyl at position 1

<221> VARIANT

<222> (4)...(4)

<223> Xaa = dehydroleucyl at position 4

<221> VARIANT

<222> (6)...(6)

<223> Xaa = norvaline at position 6

<400> 5

Xaa Gly Val Xaa Thr Xaa Ile Arg Pro

1

5

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Antiangiogenetic Peptide

<221> VARIANT

<222> (1)...(1)

<223> Xaa = R-(CH₂)_n-C(O)- where R is N-acetylamino at position 1

<221> VARIANT

<222> (2)...(2)

<223> Xaa = Sar at position 2

<221> VARIANT

<222> (5)...(5)

<223> Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at position 5

<221> VARIANT

<222> (6)...(6)

<221> VARIANT

```
<223> Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
      Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
      Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
      at position 7
```

 $\langle 222 \rangle \quad (7) \dots (7)$

Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
Tyr, Val, Pen, or Cys at position 7

 $\langle 222 \rangle \quad (11) \dots (11)$

<400> 6

Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa
1 5 10